Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30076447 | 0.83 | SMN1; SMN2 (0.54) | MEN1KMT2ACYP2C19 | |
| SCHEMBL23459251 | 0.83 | GBA1 (0.43) | TACR3MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL5355491 | 0.83 | GBA1 (0.43) | TACR3MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL6326488 | 0.83 | GBA1 (0.43) | TACR3MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL23459409 | 0.83 | GBA1 (0.43) | TACR3MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL23459412 | 0.83 | GBA1 (0.43) | TACR3MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL15971487 | 0.81 | TACR1 (0.42) | TACR3L3MBTL1MEN1KMT2AFAAH | |
| SCHEMBL6325615 | 0.81 | TACR3 (0.44) | TACR3MEN1KMT2AFAAHPOLB | |
| SCHEMBL14840505 | 0.81 | TACR1 (0.42) | TACR3L3MBTL1MEN1KMT2AFAAH | |
| SCHEMBL5354744 | 0.81 | TACR3 (0.44) | TACR3MEN1KMT2AFAAHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468748-B1 | Pyrazoloquinolones are potent parp inhibitors | ABBVIE INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8546368-B2 | Pyrazoloquinolones are potent PARP inhibitors | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2468748-A1 | Pyrazoloquinolones are potent parp inhibitors | Abbott Laboratories (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-1989204-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | Abbott Laboratories (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007095628-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | TACR3 4778/4885L3MBTL1 3332/4885MEN1 2568/4885 |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | TACR3 4778/4885L3MBTL1 3332/4885MEN1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.